Abivax shares surge as worries subside over immune drug’s cancer risk
Source ↗
👁 0
💬 0
According to Abivax, fresh data suggest malignancy rates in its trials were no higher than "background" ones for people with ulcerative colitis, clearing a key safety concern.
Comments (0)